Результаты поиска

Тандем автологическая трансплантация стволовых клеток у нескольких пациентов миэломы с минимальными остаточными заболеваниями: взрывное исследование.

Объективная аутологическая трансплантация стволовых клеток (tASCT) является жизнеспособным вариантом для пациентов с множественным миэломой (MM) повышенного риска. Минимальная остаточная болезнь (МСД), являющаяся суррогатным показателем бремени заболеваний в режиме реального времени, служит ценной мерой реагирования на эти заболевания. В ходе этого исследования была проведена оценка воздействия TAST на динамику MRD у пациентов MM.MetodsWe анализ данных из многоцентрового реестра 28 пациентов, прошедших ТАШТ в качестве прифронтового лечения в период с января 2019 и октябрь 2024. Критерии предос

Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial.

INTRODUCTION: Reducing toxicities while preserving efficacy in allogeneic stem cell transplant (allo-HCT) remains a particularly challenging problem. Different strategies to enhance the antitumor activity without increasing early and late adverse toxicities of the conditioning regimens have been investigated. METHODS: The aim of "AlloTreo" prospective phase 2 clinical trial was to evaluate the efficacy and safety of a conditioning regimen based on Treosulfan (42 g/m2) and fludarabine (https://clinicaltrials.gov/ct2/show/NCT00598624). We enrolled 108 patients with hematological diseases who re

Recent Progress of CircRNAs in Hematological Malignancies.

Circular RNAs (circRNAs) are now recognized as key regulators in the epigenetic control of genetic expression, being involved in a wide range of cellular activities such as proliferation, differentiation, and apoptosis. Their unique closed-loop structure endows them with stability and resistance to exonuclease degradation, making them not only key regulatory molecules within the cell but also promising biomarkers for disease diagnosis and prognosis, particularly in hematological malignancies. This review comprehensively explores the role of circRNAs in the pathogenesis, progression, and therap

Совпадение в полном тексте источника
… In a study involving 60 patients with ALL who received platelet transfusions, researchers identified 257 circRNAs potentially associated with platelet transfusions in ALL by constructing circRNA expression profiles and screening for differentially expressed circRNAs 87 . … Transfusion in Acute Lymphoblastic Leukemia Clin Lab 2023 69 10.7754/Clin.Lab.2023.221103 37560876 88 Alaggio R Amador C Anagnostopoulos I Attygalle AD Araujo IBO Berti E The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms Leukemia 2022 36 …

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma.

The efficacy of daratumumab depends partially on CD38 expression on multiple myeloma (MM) cells. We have previously shown that all-trans retinoic acid (ATRA) upregulates CD38 expression and reverts daratumumab-resistance ex vivo. We therefore evaluated the optimal dose, efficacy, and safety of daratumumab combined with ATRA in patients with daratumumab-refractory MM in a phase 1/2 study (NCT02751255). In part A of the study, 63 patients were treated with daratumumab monotherapy. Fifty patients with daratumumab-refractory MM were subsequently enrolled in part B and treated with daratumumab (rei

Совпадение в полном тексте источника
… . † Patients requiring platelet transfusion: part A, n = 6 (10%); part B, n = 4 (9%). ‡ Patients requiring granulocyte colony-stimulating factor support: part A, n = 12 (19%); part B, n = 6 (14%). § Any grade infusion-related reaction: 22 patients (35%). ¶ Eye infection and tooth infection (both n = …

Natural extract-derived compounds for the treatment of hematological diseases through modulation of the bone marrow microenvironment.

The bone marrow microenvironment comprises a complex network of hematopoietic stem cells, immune cells, stromal cells, and non-cellular components such as the extracellular matrix and soluble factors, collectively maintaining the homeostasis of hematopoietic stem and progenitor cells. It is highly vulnerable to pathological perturbations induced by hematologic malignancies, solid tumors, inflammatory stress, and therapeutic exposure, which collectively destabilize microenvironmental homeostasis and promote hematopoietic failure, malignant progression, and immune dysregulation. Natural products

Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.

Treatment of myelofibrosis (MF), a BCR-ABL-negative myeloproliferative neoplasm, is challenging. The only current potentially curative option, allogeneic hematopoietic stem cell transplant, is recommended for few patients. The remaining patients are treated with palliative therapies to manage MF-related anemia and splenomegaly. Identification of a mutation in the Janus kinase 2 (JAK2) gene (JAK2 V617F) in more than half of all patients with MF has prompted the discovery and clinical development of inhibitors that target JAK2. Although treatment with JAK2 inhibitors has been shown to improve sy

A Critical Appraisal of Extracorporeal Photopheresis as a Treatment Modality for Acute and Chronic Graft-Versus-Host Disease.

Although significant advances have been made in the biologic understanding of graft-versus-host disease (GVHD) and its treatment options, GVHD remains the single most challenging obstacle to the success of allogeneic hematopoietic cell transplantation (HCT) due to high risk of disabling morbidity and mortality. Extracorporeal photopheresis (ECP) has promising effects in controlling steroid-refractory GVHD, both acute and chronic, and it has been studied extensively. Its putative immunomodulatory mechanisms, while not immunosuppressive, position ECP as an attractive treatment strategy for GVHD

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia.

Immune thrombocytopenia (ITP) in pediatric patients is a common cause of isolated thrombocytopenia. Various pathophysiological mechanisms are implicated in ITP pathogenesis, including the production of autoantibodies against components of platelets (PLTs) by B-cells, the activation of the complement system, phagocytosis by macrophages mediated by Fcγ receptors, the dysregulation of T cells, and reduced bone marrow megakaryopoiesis. ITP is commonly manifested with skin and mucosal bleeding, and it is a diagnosis of exclusion. In some ITP cases, the disease is self-limiting, and treatment is not

Совпадение в полном тексте источника
… Herombopag Promotes Platelet Engraftment and Decreases Platelet Transfusion after Allogeneic Hematopoietic Stem Cell Transplantation. Eur. J. Haematol. 2023;110:527–533. doi: 10.1111/ejh.13925. 120. Extension Study of Herombopag for Pediatric Patients with Chronic Immune Thrombocytopenia. …

Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis.

IntroductionThe global pandemic of coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It seems that there is an association between blood cancer and an increased risk of severe COVID-19. This study aimed to review the literature reporting the COVID-19 outcomes in patients with hematological malignancies.Material and methodsIn this systematic review and meta-analysis, Pubmed, Embase, and Web of Science databases were searched using the following keywords: COVID-19, SARS-CoV-2, blood cancer, myeloma, lymphoma, and leukemia. All the

Donor selection for patients with HLA-homozygous haplotypes in allogeneic hematopoietic stem cell transplantation.

HighlightsRegistry analysis of first allogeneic transplant in HLA-homozygous recipients.Overall survival did not significantly differ with related donor hetero-to-homo or cord blood hetero-to-homo transplantation.Cord blood homo-to-homo transplantation was associated with inferior survival in the primary analysis.

Совпадение в полном тексте источника
… Platelet engraftment was defined as the first of 7 consecutive days with a platelet count ≥ 20 × 10⁹/L without platelet transfusion post-transplantation. Acute and chronic GVHD were diagnosed and graded according to established criteria [ 18 , 19 ]. …

Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms.

Despite the emergence of JAK inhibitors, there is a need for disease-modifying treatments for Philadelphia-negative myeloproliferative neoplasms (MPNs). JAK inhibitors ameliorate symptoms and address splenomegaly, but because of the heterogeneous contributors to the disease process, JAK inhibitor monotherapy incompletely addresses the burden of disease. The ever-growing understanding of MPN pathogenesis has provided the rationale for testing novel and targeted therapeutic agents, as monotherapies or in combination, in preclinical and clinical settings. A number of intriguing options have emerg

Post-transplant cyclophosphamide in haploidentical stem cell transplantation: evaluating the impact of transplant conditioning intensity.

BackgroundThe introduction of posttransplant cyclophosphamide (PTCy) is one of the major achievements in the field of haploidentical stem cell transplantation (haplo-HCT). The transplant conditioning intensity (TCI) score is a refined classification of conditioning regimens that assigns weight scores to conditioning regimen components. The aim of our analysis was twofold: to assess the effect on transplant outcomes of combining PTCy with calcineurin inhibitor + mycophenolate mofetil (MMF) instead of mTOR inhibitor + MMF for GvHD prophylaxis, and to assess the effect of stratification by condit

Совпадение в полном тексте источника
… Platelet engraftment was defined as the first of seven consecutive days with platelet counts ≥ 20 × 10 9 /L without platelet transfusions. …

Criteria for referring pediatric and adult patients with hematological diseases to palliative care: Consensus of the Brazilian Association of Hematology, hemotherapy and cell therapy (2025).

Palliative care is, according to the World Health Organization (WHO), "a global ethical responsibility" and crucial to person-centered healthcare, for the relief of physical and psychological symptoms and social and spiritual suffering, impacting the improvement of the quality of life not only of pediatric and adult patients dealing with life-threatening illnesses, but also of their families. Despite the growing recognition of palliative care in the hematological setting and the increase in the number of publications on the subject, the available data are still scarce and limited. The objectiv

Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.

The Janus kinase inhibitor ruxolitinib is approved for the treatment of myelofibrosis (MF) and improved overall survival (OS) versus control therapy in the phase 3 COMFORT trials. The aim of this retrospective analysis was to examine the real-world impact of ruxolitinib on OS in patients with MF. The US Medicare Fee-for-Service claims database (parts A/B/D) was used to identify patients with ≥ 1 inpatient or ≥ 2 outpatient claims with an MF diagnosis (January 2010-December 2017). Eligible patients with MF were ≥ 65 years old (intermediate-1 or higher risk based on age). Patients were divided i

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.

This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, a selective proteasome inhibitor, in patients with multiple myeloma and varying degrees of renal impairment, including patients on chronic hemodialysis. Patients were grouped by creatinine clearance: >80 ml/min, 50-80 ml/min, 30-49 ml/min, <30 ml/min and chronic hemodialysis. Carfilzomib was administered on days 1, 2, 8, 9, 15 and 16 in 28-day cycles: 15 mg/m(2) (Cycle 1), 20 mg/m(2) (Cycle 2) and 27 mg/m(2) (Cycles 3+). There were no differences in carfilzomib clearance or exposure among pa

Distress and quality of life after autologous stem cell transplantation: a randomized clinical trial to evaluate the outcome of a web-based stepped care intervention.

BackgroundPsychological distress (i.e. depression and anxiety) is a strong predictor of functional status and other aspects of quality of life in autologous stem cell transplantation following high-dose chemotherapy. Treatment of psychological distress is hypothesized to result in improvement of functional status and other aspects of quality of life. The aim is to evaluate the outcome of stepped care for psychological distress on functional status and other aspects of quality of life in patients with hematological malignancy treated with autologous stem cell transplantation.Methods/designThe s

Vascular Access Devices for Stem Cell Transplantation: A Review of Catheter Types-A Crucial Step Towards the Enhancement of Patient Care.

Central venous access devices (CVADs) play a pivotal role in managing stem cell recipients, providing reliable access for the administration of chemotherapy, blood products, progenitor infusion, parenteral nutrition, and other crucial treatments. This review critically evaluates the various types of CVADs commonly employed in transplant settings, examining their indications, complications, and best practices to enhance patient outcomes. Moreover, it emphasizes the significance of broadening the selection algorithm for vascular devices and incorporating patient expectations and comfort into rou

Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes.

BackgroundHigh-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains an effective treatment for non-Hodgkin lymphoma (NHL). The limited availability of carmustine has prompted the exploration of novel alternative conditioning regimens. This study aimed to compare the efficacy and safety profile of GBM/GBC (gemcitabine, busulfan, and melphalan or cyclophosphamide) conditioning compared with the standard BEAM/BEAC regimens (carmustine, etoposide, cytarabine, and melphalan or cyclophosphamide) for ASCT in patients with NHL.MethodsA retrospective analysis was conducted

Совпадение в полном тексте источника
… Platelet engraftment was defined as a platelet count exceeding 20 × 10 9 /L without the need for platelet transfusions over a period of at least seven consecutive days. Transplant‐related toxicities were evaluated using the NCI Common Terminology Criteria for Adverse Events (CTCAE v5.0). …

The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O009-O155).

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Probiotics and nanoparticle-mediated nutrient delivery in the management of transfusion-supported diseases.

Bone marrow is vital for hematopoiesis, producing blood cells essential for oxygen transport, immune defense, and clotting. However, disorders like leukemia, lymphoma, aplastic anemia, and myelodysplastic syndromes can severely disrupt its function, leading to life-threatening complications. Traditional treatments, including chemotherapy and stem cell transplants, have significantly improved patient outcomes but are often associated with severe side effects and limitations, necessitating the exploration of safer, more targeted therapeutic strategies. Nanotechnology has emerged as a promising a